NGM707 + Pembrolizumab for Cancer

Recruiting at40 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: NGM Biopharmaceuticals, Inc

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug called NGM707, both by itself and with another drug, Pembrolizumab. It targets patients with very advanced or spreading solid tumors. The treatment aims to boost the immune system to better fight cancer.

Research Team

Chief Medical Officer

Principal Investigator

NGM Biopharmaceuticals, Inc

Eligibility Criteria

This trial is for adults with advanced or metastatic solid tumors who have tried all other treatments without success, or can't tolerate them, and are in good physical condition. They must have recovered from previous therapy side effects and have proper bone marrow, kidney, and liver function.

Inclusion Criteria

I am fully active or restricted in physically strenuous activity but can do light work.

My bone marrow, kidney, and liver are functioning well.

My cancer did not respond to or I couldn't tolerate all treatments I was eligible for.

Exclusion Criteria

I have not had treatments targeting ILT2/ILT4 or HLA-G.

Treatment Details

Interventions

• NGM707 (Monoclonal Antibodies)
• Pembrolizumab (Monoclonal Antibodies)

Trial Overview The study tests NGM707 alone or combined with pembrolizumab to treat various cancers. It aims to see how well these treatments work on their own or together against different types of advanced cancer.

Participant Groups

Group I: NGM707 Monotherapy Dose Expansion Arm F Experimental Treatment 1 Intervention

NGM707 in Ovarian

Group II: NGM707 Monotherapy Dose Expansion Arm E Experimental Treatment 1 Intervention

NGM707 in CRC

Group III: NGM707 Monotherapy Dose Expansion Arm D Experimental Treatment 1 Intervention

NGM707 in RCC

Group IV: NGM707 Monotherapy Dose Escalation Experimental Treatment 1 Intervention

Part 1a Single Agent Dose Escalation

Group V: NGM707 Combination Dose Finding with pembrolizumab (KEYTRUDA®) Experimental Treatment 1 Intervention

Part 1b NGM707 plus pembrolizumab (KEYTRUDA®)

Group VI: NGM707 Combination Dose Expansion Arm C Experimental Treatment 1 Intervention

NGM707 with pembrolizumab (KEYTRUDA®) in SCCHN

Group VII: NGM707 Combination Dose Expansion Arm B Experimental Treatment 1 Intervention

NGM707 with pembrolizumab (KEYTRUDA®) in Non-Squamous NSCLC

Group VIII: NGM707 Combination Dose Expansion Arm A Experimental Treatment 1 Intervention

NGM707 with pembrolizumab (KEYTRUDA®) in Squamous NSCLC

Who Is Running the Clinical Trial?

NGM Biopharmaceuticals, Inc

Lead Sponsor

Trials

25

Recruited

2,500+

Merck Sharp & Dohme LLC

Industry Sponsor

Trials

4,096

Recruited

5,232,000+

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University